Other BETi, including compound 870, I-BET 762, I-BET151, MS436, MS417, GSK525762A, have also demonstrated inhibitory effects on the stemness of basal-like breast cancer [157], ALDH activity [158], reprogramming of acute myeloid leukemia stem cells [171] and ESC multi-differentiation [108]. This evidence concerns the gene LDHA and breast cancer.